• Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. 

  Witkiewicz, AK; Chung, S; Brough, R; Vail, P; Franco, J; Lord, CJ; Knudsen, ES (2018-01)

  Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor suppressor, suggesting a target for precision intervention. Here, we use drug screens to identify agents specifically ...
• CancerGD: a resource for identifying and interpreting genetic dependencies in cancer 

  Bridgett, S; Campbell, J; Lord, C; Ryan, C (2016-10-26)

  Abstract Genes whose function is selectively essential in the presence of cancer associated genetic aberrations represent promising targets for the development of precision therapeutics. Here we present CancerGD ( ...
• Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. 

  Quigley, D; Alumkal, JJ; Wyatt, AW; Kothari, V; Foye, A; Lloyd, P; Aggarwal, R; Kim, W; Lu, E; Schwartzman, J; Beja, K; Annala, M; Das, R; Diolaiti, M; Pritchard, C; Thomas, G; Tomlins, S; Knudsen, K; Lord, CJ; Ryan, C; Youngren, J; Beer, TM; Ashworth, A; Small, EJ; Feng, FY (2017-09)

  Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2 HRR defects confer synthetic lethality to PARP inhibitors (PARPi) ...
• Orally-bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma 

  Poon, E; Jamin, Y; Kwok, C; Barker, K; Urban, Z; Thway, K; Hallsworth, A; Box, G; Lazaro, G; Calton, EA; Martins da Costa, B; Valenti, M; De Haven Brandon, A; Webber, HT; Christova, R; Boysen, G; Ford, A; Clarke, P; De Bono, J; Blagg, J; Robinson, S; Eccles, S; Vivanco, I; Workman, P; Chesler, L
• Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. 

  Lupo, B; Sassi, F; Pinnelli, M; Galimi, F; Zanella, ER; Vurchio, V; Migliardi, G; Gagliardi, PA; Puliafito, A; Manganaro, D; Luraghi, P; Kragh, M; Pedersen, MW; Horak, ID; Boccaccio, C; Medico, E; Primo, L; Nichol, D; Spiteri, I; Heide, T; Vatsiou, A; Graham, TA; Élez, E; Argiles, G; Nuciforo, P; Sottoriva, A; Dienstmann, R; Pasini, D; Grassi, E; Isella, C; Bertotti, A; Trusolino, L (2020-08)

  Blockade of epidermal growth factor receptor (EGFR) causes tumor regression in some patients with metastatic colorectal cancer (mCRC). However, residual disease reservoirs typically remain even after maximal response to ...
• Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. 

  Pettitt, SJ; Frankum, JR; Punta, M; Lise, S; Alexander, J; Chen, Y; Yap, TA; Haider, S; Tutt, ANJ; Lord, CJ (2020-07-22)

  Reversion mutations in BRCA1 or BRCA2 are associated with resistance to PARP inhibitors and platinum. To better understand the nature of these mutations, we collated, codified, and analyzed more than 300 reversions. This ...
• Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. 

  Young, K; Lawlor, RT; Ragulan, C; Patil, Y; Mafficini, A; Bersani, S; Antonello, D; Mansfield, D; Cingarlini, S; Landoni, L; Pea, A; Luchini, C; Piredda, L; Kannan, N; Nyamundanda, G; Morganstein, D; Chau, I; Wiedenmann, B; Milella, M; Melcher, A; Cunningham, D; Starling, N; Scarpa, A; Sadanandam, A (2020-09-03)

  OBJECTIVE:A comprehensive analysis of the immune landscape of pancreatic neuroendocrine tumours (PanNETs) was performed according to clinicopathological parameters and previously defined molecular subtypes to identify ...
• Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma. 

  George, SL; Lorenzi, F; King, D; Hartlieb, S; Campbell, J; Pemberton, H; Toprak, UH; Barker, K; Tall, J; da Costa, BM; van den Boogaard, ML; Dolman, MEM; Molenaar, JJ; Bryant, HE; Westermann, F; Lord, CJ; Chesler, L (2020-08-23)

  BACKGROUND:In neuroblastoma, genetic alterations in ATRX, define a distinct poor outcome patient subgroup. Despite the need for new therapies, there is a lack of available models and a dearth of pre-clinical research. ...
• Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study. 

  Loveday, C; Sud, A; Jones, ME; Broggio, J; Scott, S; Gronthound, F; Torr, B; Garrett, A; Nicol, DL; Jhanji, S; Boyce, SA; Williams, M; Barry, C; Riboli, E; Kipps, E; McFerran, E; Muller, DC; Lyratzopoulos, G; Lawler, M; Abulafi, M; Houlston, RS; Turnbull, C (2020-08-27)

  OBJECTIVE:To evaluate the impact of faecal immunochemical testing (FIT) prioritisation to mitigate the impact of delays in the colorectal cancer (CRC) urgent diagnostic (2-week-wait (2WW)) pathway consequent from the ...
• Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. 

  Tacconi, EM; Badie, S; De Gregoriis, G; Reisländer, T; Lai, X; Porru, M; Folio, C; Moore, J; Kopp, A; Baguña Torres, J; Sneddon, D; Green, M; Dedic, S; Lee, JW; Batra, AS; Rueda, OM; Bruna, A; Leonetti, C; Caldas, C; Cornelissen, B; Brino, L; Ryan, A; Biroccio, A; Tarsounas, M (2019-07)

  Due to compromised homologous recombination (HR) repair, BRCA1- and BRCA2-mutated tumours accumulate DNA damage and genomic rearrangements conducive of tumour progression. To identify drugs that target specifically ...
• Genetic predisposition to chronic lymphocytic leukemia 

  Law, PJ; Houlston, RS (LIPPINCOTT WILLIAMS & WILKINS, 2019-06-01)
• An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer 

  Rimm, DL; Leung, SCY; McShane, LM; Bai, Y; Bane, AL; Bartlett, JMS; Bayani, J; Chang, MC; Dean, M; Denkert, C; Enwere, EK; Galderisi, C; Gholap, A; Hugh, JC; Jadhav, A; Kornaga, EN; Laurinavicius, A; Levenson, R; Lima, J; Miller, K; Pantanowitz, L; Piper, T; Ruan, J; Srinivasan, M; Virk, S; Wu, Y; Yang, H; Hayes, DF; Nielsen, TO; Dowsett, M (Springer Nature, 2019-01)
• Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets. 

  Cooley, R; Kara, N; Hui, NS; Tart, J; Roustan, C; George, R; Hancock, DC; Binkowski, BF; Wood, KV; Ismail, M; Downward, J (2020-01)

  Targeting the interaction of proteins with weak binding affinities or low solubility represents a particular challenge for drug screening. The NanoLuc â ® Binary Technology (NanoBiT â ®) was originally developed to detect ...
• Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. 

  Zhang, YD; Hurson, AN; Zhang, H; Choudhury, PP; Easton, DF; Milne, RL; Simard, J; Hall, P; Michailidou, K; Dennis, J; Schmidt, MK; Chang-Claude, J; Gharahkhani, P; Whiteman, D; Campbell, PT; Hoffmeister, M; Jenkins, M; Peters, U; Hsu, L; Gruber, SB; Casey, G; Schmit, SL; O'Mara, TA; Spurdle, AB; Thompson, DJ; Tomlinson, I; De Vivo, I; Landi, MT; Law, MH; Iles, MM; Demenais, F; Kumar, R; MacGregor, S; Bishop, DT; Ward, SV; Bondy, ML; Houlston, R; Wiencke, JK; Melin, B; Barnholtz-Sloan, J; Kinnersley, B; Wrensch, MR; Amos, CI; Hung, RJ; Brennan, P; McKay, J; Caporaso, NE; Berndt, SI; Birmann, BM; Camp, NJ; Kraft, P; Rothman, N; Slager, SL; Berchuck, A; Pharoah, PDP; Sellers, TA; Gayther, SA; Pearce, CL; Goode, EL; Schildkraut, JM; Moysich, KB; Amundadottir, LT; Jacobs, EJ; Klein, AP; Petersen, GM; Risch, HA; Stolzenberg-Solomon, RZ; Wolpin, BM; Li, D; Eeles, RA; Haiman, CA; Kote-Jarai, Z; Schumacher, FR; Al Olama, AA; Purdue, MP; Scelo, G; Dalgaard, MD; Greene, MH; Grotmol, T; Kanetsky, PA; McGlynn, KA; Nathanson, KL; Turnbull, C; Wiklund, F; Breast Cancer Association Consortium (BCAC); Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON); Colon Cancer Family Registry (CCFR); Transdisciplinary Studies of Genetic Variation in Colorectal Cancer (CORECT); Endometrial Cancer Association Consortium (ECAC); Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO); Melanoma Genetics Consortium (GenoMEL); Glioma International Case-Control Study (GICC); International Lung Cancer Consortium (ILCCO); Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium; International Consortium of Investigators Working on Non-Hodgkin’s Lymphoma Epidemiologic Studies (InterLymph); Ovarian Cancer Association Consortium (OCAC); Oral Cancer GWAS; Pancreatic Cancer Case-Control Consortium (PanC4); Pancreatic Cancer Cohort Consortium (PanScan); Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL); Renal Cancer GWAS; Testicular Cancer Consortium (TECAC); Chanock, SJ; Chatterjee, N; Garcia-Closas, M (2020-07-03)

  Genome-wide association studies (GWAS) have led to the identification of hundreds of susceptibility loci across cancers, but the impact of further studies remains uncertain. Here we analyse summary-level data from GWAS of ...
• Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. 

  Jackson, GH; Pawlyn, C; Cairns, DA; Striha, A; Collett, C; Waterhouse, A; Jones, JR; Wilson, J; Taylor, C; Kishore, B; Garg, M; Williams, CD; Karunanithi, K; Lindsay, J; Jenner, MW; Cook, G; Russell, NH; Drayson, MT; Kaiser, MF; Owen, RG; Gregory, WM; Davies, FE; Morgan, GJ; UK NCRI Haemato-oncology Clinical Studies Group (2020-07-12)

  Second-generation immunomodulatory agents, such as lenalidomide, have a more favourable side-effect profile than the first-generation thalidomide, but their optimum combination and duration for patients with newly diagnosed ...
• Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. 

  Fotiadis, N; De Paepe, KN; Bonne, L; Khan, N; Riddell, A; Turner, N; Starling, N; Gerlinger, M; Rao, S; Chau, I; Cunningham, D; Koh, D-M (2020-07-14)

  OBJECTIVES:Percutaneous liver biopsy (PLB) poses specific challenges in oncological patients such as bleeding and tumour seeding. This study's aim was to compare a coaxial (C-PLB) and non-coaxial (NC-PLB) biopsy technique ...
• Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer. 

  Zecchin, D; Moore, C; Michailidis, F; Horswell, S; Rana, S; Howell, M; Downward, J (2020-08)

  Triple-negative breast cancer (TNBC) has poorer prognosis compared to other types of breast cancers due to the lack of effective therapies and markers for patient stratification. Loss of PTEN tumor suppressor gene expression ...
• Immune surveillance in clinical regression of pre-invasive squamous cell lung cancer. 

  Pennycuick, A; Teixeira, VH; AbdulJabbar, K; Raza, SEA; Lund, T; Akarca, AU; Rosenthal, R; Kalinke, L; Chandrasekharan, DP; Pipinikas, CP; Lee-Six, H; Hynds, RE; Gowers, KHC; Henry, JY; Millar, FR; Hagos, YB; Denais, C; Falzon, M; Moore, DA; Antoniou, S; Durrenberger, PF; Furness, AJS; Carroll, B; Marceaux, C; Asselin-Labat, M-L; Larson, W; Betts, C; Coussens, LM; Thakrar, RM; George, J; Swanton, C; Thirlwell, C; Campbell, PJ; Marafioti, T; Yuan, Y; Quezada, SA; McGranahan, N; Janes, SM (2020-07-20)

  Before squamous cell lung cancer develops, pre-cancerous lesions can be found in the airways. From longitudinal monitoring, we know that only half of such lesions become cancer, whereas a third spontaneously regress. While ...
• Pathway Analysis of Renal Cell Carcinoma Genome-Wide Association Studies Identifies Novel Associations. 

  Purdue, MP; Song, L; Scélo, G; Houlston, RS; Wu, X; Sakoda, LC; Thai, K; Graff, RE; Rothman, N; Brennan, P; Chanock, SJ; Yu, K (2020-07-30)

  BACKGROUND:Much of the heritable risk of renal cell carcinoma (RCC) associated with common genetic variation is unexplained. New analytic approaches have been developed to increase the discovery of risk variants in genome-wide ...
• Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. 

  Kaiser, M; Beksaç, M; Gulbrandsen, N; Schjesvold, F; Hájek, R; Moreau, P; de Arriba de la Fuente, F; Mateos, M-V; West, S; Spencer, A; Rajkumar, SV; Suryanarayan, K; Czorniak, M; Li, C; Teng, Z; Labotka, R; Dimopoulos, MA (2020-08)

  The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study (NCT02181413) demonstrated improved progression-free survival with ixazomib maintenance versus placebo post autologous stem cell transplant (ASCT) in ...

View more